Equitoxicity of bolus and infusional etoposide: results of a multicenter randomised trial of the German High-Grade Non-Hodgkins Lymphoma Study Group (DSHNHL) in elderly patients with refractory or relapsing aggressive non-Hodgkin lymphoma using the CEMP regimen (cisplatinum, etoposide, mitoxantrone and prednisone).

Carsten Zwick; Josef Birkmann; Norma Peter; Heinrich Bodenstein; Roland Fuchs; Mathias Hänel; Marcel Reiser; Manfred Hensel; Michael Clemens; Samira Zeynalova; Marita Ziepert; Michael Pfreundschuh

doi:10.1007/s00277-008-0500-1

Equitoxicity of bolus and infusional etoposide: results of a multicenter randomised trial of the German High-Grade Non-Hodgkins Lymphoma Study Group (DSHNHL) in elderly patients with refractory or relapsing aggressive non-Hodgkin lymphoma using the CEMP regimen (cisplatinum, etoposide, mitoxantrone and prednisone).

Carsten Zwick, Josef Birkmann, Norma Peter, Heinrich Bodenstein, Roland Fuchs, Mathias Hänel, Marcel Reiser, Manfred Hensel, Michael Clemens, Samira Zeynalova, Marita Ziepert, Michael Pfreundschuh

Department of Internal Medicine V, Division of Oncology and Hematology

Research output: Contribution to journal › Original Article › peer-review

4 Citations (Web of Science)

Original language	English
Pages (from-to)	717-726
Journal	ANNALS OF HEMATOLOGY
Volume	87
Issue number	9
DOIs	https://doi.org/10.1007/s00277-008-0500-1
Publication status	Published - 2008

Keywords

BONE-MARROW-TRANSPLANTATION
HIGH-DOSE CYTARABINE
CELL LUNG-CANCER
SALVAGE CHEMOTHERAPY
FOLLOW-UP
PHASE-II
COMBINATION CHEMOTHERAPY
INTENSIVE CHEMOTHERAPY
EPOCH CHEMOTHERAPY
MALIGNANT-LYMPHOMA

Access to Document

10.1007/s00277-008-0500-1

Cite this

Zwick, C., Birkmann, J., Peter, N., Bodenstein, H., Fuchs, R., Hänel, M., Reiser, M., Hensel, M., Clemens, M., Zeynalova, S., Ziepert, M., & Pfreundschuh, M. (2008). Equitoxicity of bolus and infusional etoposide: results of a multicenter randomised trial of the German High-Grade Non-Hodgkins Lymphoma Study Group (DSHNHL) in elderly patients with refractory or relapsing aggressive non-Hodgkin lymphoma using the CEMP regimen (cisplatinum, etoposide, mitoxantrone and prednisone). ANNALS OF HEMATOLOGY , 87(9), 717-726. https://doi.org/10.1007/s00277-008-0500-1

Zwick, Carsten ; Birkmann, Josef ; Peter, Norma et al. / Equitoxicity of bolus and infusional etoposide: results of a multicenter randomised trial of the German High-Grade Non-Hodgkins Lymphoma Study Group (DSHNHL) in elderly patients with refractory or relapsing aggressive non-Hodgkin lymphoma using the CEMP regimen (cisplatinum, etoposide, mitoxantrone and prednisone). In: ANNALS OF HEMATOLOGY 2008 ; Vol. 87, No. 9. pp. 717-726.

@article{e2319eac94314136b673541410d64dee,

title = "Equitoxicity of bolus and infusional etoposide: results of a multicenter randomised trial of the German High-Grade Non-Hodgkins Lymphoma Study Group (DSHNHL) in elderly patients with refractory or relapsing aggressive non-Hodgkin lymphoma using the CEMP regimen (cisplatinum, etoposide, mitoxantrone and prednisone).",

keywords = "BONE-MARROW-TRANSPLANTATION, HIGH-DOSE CYTARABINE, CELL LUNG-CANCER, SALVAGE CHEMOTHERAPY, FOLLOW-UP, PHASE-II, COMBINATION CHEMOTHERAPY, INTENSIVE CHEMOTHERAPY, EPOCH CHEMOTHERAPY, MALIGNANT-LYMPHOMA",

author = "Carsten Zwick and Josef Birkmann and Norma Peter and Heinrich Bodenstein and Roland Fuchs and Mathias H{\"a}nel and Marcel Reiser and Manfred Hensel and Michael Clemens and Samira Zeynalova and Marita Ziepert and Michael Pfreundschuh",

year = "2008",

doi = "10.1007/s00277-008-0500-1",

language = "English",

volume = "87",

pages = "717--726",

journal = "ANNALS OF HEMATOLOGY ",

issn = "0939-5555",

number = "9",

}

Zwick, C, Birkmann, J, Peter, N, Bodenstein, H, Fuchs, R, Hänel, M, Reiser, M, Hensel, M, Clemens, M, Zeynalova, S, Ziepert, M & Pfreundschuh, M 2008, 'Equitoxicity of bolus and infusional etoposide: results of a multicenter randomised trial of the German High-Grade Non-Hodgkins Lymphoma Study Group (DSHNHL) in elderly patients with refractory or relapsing aggressive non-Hodgkin lymphoma using the CEMP regimen (cisplatinum, etoposide, mitoxantrone and prednisone).', ANNALS OF HEMATOLOGY , vol. 87, no. 9, pp. 717-726. https://doi.org/10.1007/s00277-008-0500-1

Equitoxicity of bolus and infusional etoposide: results of a multicenter randomised trial of the German High-Grade Non-Hodgkins Lymphoma Study Group (DSHNHL) in elderly patients with refractory or relapsing aggressive non-Hodgkin lymphoma using the CEMP regimen (cisplatinum, etoposide, mitoxantrone and prednisone). / Zwick, Carsten; Birkmann, Josef; Peter, Norma et al.
In: ANNALS OF HEMATOLOGY , Vol. 87, No. 9, 2008, p. 717-726.

Research output: Contribution to journal › Original Article › peer-review

TY - JOUR

T1 - Equitoxicity of bolus and infusional etoposide: results of a multicenter randomised trial of the German High-Grade Non-Hodgkins Lymphoma Study Group (DSHNHL) in elderly patients with refractory or relapsing aggressive non-Hodgkin lymphoma using the CEMP regimen (cisplatinum, etoposide, mitoxantrone and prednisone).

AU - Zwick, Carsten

AU - Birkmann, Josef

AU - Peter, Norma

AU - Bodenstein, Heinrich

AU - Fuchs, Roland

AU - Hänel, Mathias

AU - Reiser, Marcel

AU - Hensel, Manfred

AU - Clemens, Michael

AU - Zeynalova, Samira

AU - Ziepert, Marita

AU - Pfreundschuh, Michael

PY - 2008

Y1 - 2008

KW - BONE-MARROW-TRANSPLANTATION

KW - HIGH-DOSE CYTARABINE

KW - CELL LUNG-CANCER

KW - SALVAGE CHEMOTHERAPY

KW - FOLLOW-UP

KW - PHASE-II

KW - COMBINATION CHEMOTHERAPY

KW - INTENSIVE CHEMOTHERAPY

KW - EPOCH CHEMOTHERAPY

KW - MALIGNANT-LYMPHOMA

U2 - 10.1007/s00277-008-0500-1

DO - 10.1007/s00277-008-0500-1

M3 - Original Article

C2 - 18587579

SN - 0939-5555

VL - 87

SP - 717

EP - 726

JO - ANNALS OF HEMATOLOGY

JF - ANNALS OF HEMATOLOGY

IS - 9

ER -

Zwick C, Birkmann J, Peter N, Bodenstein H, Fuchs R, Hänel M et al. Equitoxicity of bolus and infusional etoposide: results of a multicenter randomised trial of the German High-Grade Non-Hodgkins Lymphoma Study Group (DSHNHL) in elderly patients with refractory or relapsing aggressive non-Hodgkin lymphoma using the CEMP regimen (cisplatinum, etoposide, mitoxantrone and prednisone). ANNALS OF HEMATOLOGY . 2008;87(9):717-726. doi: 10.1007/s00277-008-0500-1